share_log

Scotiabank Initiates Coverage On Blueprint Medicines With Sector Outperform Rating, Announces Price Target of $150

Benzinga ·  Mar 7 22:41  · Ratings

Scotiabank analyst Louise Chen initiates coverage on Blueprint Medicines (NASDAQ:BPMC) with a Sector Outperform rating and announces Price Target of $150.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 265

Recommended

Write a comment